Longwood Fund is a Boston venture firm that founds and funds early biotech companies, several of them in cancer.
Longwood Fund is a Boston-based healthcare venture firm founded in 2010 that creates and invests in early-stage biotechnology companies, frequently as a founding investor working with academic scientists. Oncology has been a recurring area, including immuno-oncology and precision medicine companies. Portfolio links in OnCo are derived from the startup records that name it.
| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| DEM BioPharma Cambridge, MA, US | Growth stage | biotech | Colorectal cancer | Launch financing 2022, $70M |
| Neomorph San Diego, CA, US | Startup | biotech | Renal cell carcinoma | Series B 2026, $100M |
| Photys Therapeutics Boston, MA, US | Startup | biotech | Series A 2022, $75M | |
| Sidewinder Therapeutics San Diego, CA, US | Startup | biotech | Non-small-cell lung cancerHead and neck squamous cell carcinomaColorectal cancer | Series B 2026, $137M |
| Solu Therapeutics Boston, MA, US | Startup | biotech | Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasmsAcute myeloid leukaemia | Series A 2025, $41M |
Shares Solu Therapeutics, Sidewinder Therapeutics and the tag vc.
Shares Neomorph and the tag vc.
Shares Photys Therapeutics and the tag vc.
Shares Solu Therapeutics and the tag vc.
Shares Photys Therapeutics and the tag vc.
Shares Sidewinder Therapeutics and the tag vc.
Shares Sidewinder Therapeutics and the tag vc.
Shares Sidewinder Therapeutics and the tag vc.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/